Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine

Cladribine has been approved for the treatment of multiple sclerosis (MS) and its administration results in a long-lasting depletion of lymphocytes. As lymphopenia is known to hamper immune responses to vaccination, we evaluated the immunogenicity of the influenza vaccine in patients undergoing clad...

Descripció completa

Dades bibliogràfiques

Autors principals:	Leoni Rolfes, Steffen Pfeuffer, Jelena Skuljec, Xia He, Chuanxin Su, Sinem-Hilal Oezalp, Marc Pawlitzki, Tobias Ruck, Melanie Korsen, Konstanze Kleinschnitz, Derya Aslan, Tim Hagenacker, Christoph Kleinschnitz, Sven G. Meuth, Refik Pul
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2023-04-01
Col·lecció:	Cells
Matèries:	multiple sclerosis cladribine immunization influenza vaccination
Accés en línia:	https://www.mdpi.com/2073-4409/12/9/1243
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!